Original Title: Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. Reference: Stone, M.D. for the ABSORB III Investigators. N Engl J Med 2015;373:1905-1915. The ABSORB III is part of a series of randomized studies that test bioresorbable scaffolds in the clinical practice (ABSORB II, EVERBIO II, ABSORB Japan, and ABSORB IV). 2008 patients were randomized; 60% had...
Original Title: Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention (RECLOSE-3 study). Reference: Valenti R, et al. JACC Cardiovasc Interv. 2015 Oct;8(12):1563-70. Clopidogrel Nonresponders have higher risk of adverse events (cardiovascular death and stent thrombosis) compared to responders. Studies published so far have failed to demonstrate the use of platelet function tests in ACS patient...
Original Title: Regression of Paravalvular Aortic Regurgitation and Remodeling of Self-Expanding Transcatheter Aortic Valve. An Observation From the CoreValve U.S. Pivotal Trial. Reference: Jae K. Oh et al. J Am Coll Cardiol Img. 2015, online first. The aim of this study was to describe the natural evolution and the clinical significance of paravalvular aortic insufficiency after...
Original Title: Individualizing Treatment Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Analysis from the DAPT Study. Presenter: Yeh RW. Optimal dual antiplatelet therapy duration for patients receiving stents has started to become clearer, but a new scoring method (DAPT Score) may help single out patients who could either benefit or suffer from extended...
Original Title: Cholesterol treatment targets and clinical outcomes: a JUPITER trial update. Presenter: Paul Ridker. The lower the LDL cholesterol levels, the less adverse cardiovascular events in men and women initially healthy, according to an analysis of the JUPITER trial. Findings could help inform about the optimal LDL goals in primary prevention. To explore the...
Fundamentos: O objetivo desse estudo foi avaliar se a trombectomia manual de rotina reduz a obstrução microvascular (MVO) avaliada pela ressonância cardíaca em pacientes com IAM com supradesnivelamento do segmento ST (IAMCSST) subagudo com 12 a 48 horas após o início dos sintomas. Métodos e resultados: Estudo prospectivo, multicêntrico, com 152 pacientes com IAMCSST entre 12 a...
Original Title: Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk Reference: Philip Urban et al. N Engl J Med. 2015 Oct 14. [Epub ahead of print]. High bleeding risk patients undergoing PCI usually receive conventional bare metal stents (BMS) to allow the shortest possible DAPT (dual antiplatelet therapy), usually a month long. This...
Extending dual antiaggregation therapy (DAT) from 12 to 48 months appears not to offer extra protection after DES implantation in patients with no adverse ischemic events during the first year, neither does it increase the risk of severe bleeding. The OPTIDUAL study was carried out in 58 centers and included 1.385 patients one year after...
Though the benefit of FFR (fractional flow reserve) over angiography is statistically important only over the first 2 years, this pattern is maintained at long term according to FAME 5 year follow up, presented at the ECS and simultaneously published in The Lancet. Between the second and fifth year, the number of patients at risk...
The Latin American Society or Interventional Cardiology continues its SOLidary Program performing interventional procedures at each of SOLACI Regional Sessions SOLACI recognizes the urge to develop a Social Responsibility program, to channel efforts, human and economic resources, to offer the best cardiovascular intervention to assist those most in need. SOLACI SOLidary Program enablesthe accord between...